Transaxillary subpectoral augmentation mammaplasty: a single surgeon's 20-year experience.

Aesthetic surgery journal 2011 Vol.31(7) p. 781-801

Huang GJ, Wichmann JL, Mills DC

관련 도메인

Abstract

[BACKGROUND] Transaxillary subpectoral augmentation mammaplasty (TASPA) is not widely accepted due to perceived limitations in pocket access, visualization, control, and subsequent risk for postoperative complications. Current published data do little to substantiate or refute those claims.

[OBJECTIVE] A retrospective chart review of a single surgeon's 20-year experience with the TASPA technique was undertaken to assess the incidence of total secondary procedures, implant-related revisions, and reoperations unrelated to the implant.

[METHODS] The senior author (DCM) performed 1776 primary TASPA procedures from January 1989 through December 2008. Of those, 94 patients did not meet inclusion criteria, leaving a total of 1682 records for analysis. Data reviewed included age, date of surgery, race, implant size and type, manufacturer, and reasons for reoperation.

[RESULTS] Average age was 32.7 ± 8.1 years (range, 16-62). Average implant size was 438.5 ± 51.5 cc (range, 270-630). Implants from Allergan/Inamed/McGhan (Irvine, CA), Dow-Corning (Midland, MI), Mentor (Santa Barbara, CA), and Surgitek (Racine, PA) were inserted (n = 2094 saline, n = 1270 silicone). Mean follow-up time was 37.9 ± 45.4 months (range, one month to 19.8 years). Excluding staged mastopexies and treatment for breast cancer, total secondary procedures were required in 225 patients (13.4%). Implant-related revisions included malposition (2.97%), size change (2.5%), and capsular contracture (1.9%). Perioperatively, no infections occurred, and two patients (0.12%) experienced hematoma. Most reoperations (62.8%) were performed through the axilla. Comparison to published data showed an equal or lower rate of capsular contracture, hematoma, and infection with the TASPA approach.

[CONCLUSIONS] Given its advantages of an inconspicuous scar, decreased infection, and decreased capsular contracture, TASPA can be safely offered to patients as an option in breast augmentation.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
합병증 capsular contracture 피막구축 dict 3
시술 mammaplasty 유방성형술 dict 2
해부 breast 유방 dict 2
합병증 hematoma 혈종 dict 2
합병증 infection 감염 dict 2
기법 subpectoral 근막하 평면 dict 2
시술 breast augmentation 유방성형술 dict 1
합병증 implant-related scispacy 1
합병증 axilla scispacy 1
합병증 scar scispacy 1
약물 DCM C0007193
Cardiomyopathy, Dilated
scispacy 1
약물 Allergan/Inamed/McGhan scispacy 1
약물 silicone C0037114
silicones
scispacy 1
약물 ± 45.4 months scispacy 1
약물 [BACKGROUND] Transaxillary subpectoral augmentation scispacy 1
약물 [OBJECTIVE] A scispacy 1
약물 saline scispacy 1
약물 [CONCLUSIONS] scispacy 1
질환 breast cancer C0006142
Malignant neoplasm of breast
scispacy 1
질환 Implant-related scispacy 1
질환 infections C0851162
Infections of musculoskeletal system
scispacy 1
기타 patients scispacy 1
기타 capsular scispacy 1

MeSH Terms

Adolescent; Adult; Axilla; Breast Implantation; Breast Implants; Female; Follow-Up Studies; Hematoma; Humans; Implant Capsular Contracture; Middle Aged; Reoperation; Retrospective Studies; Silicone Gels; Sodium Chloride; Treatment Outcome; Young Adult

📑 인용 관계

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문